🇺🇸 US Stock Screener ← Switch market ⚡ HerAI

Arcus Biosciences, Inc. RCUS R2KR3KPHARMA

Healthcare · Biotechnology · United States
Financial distress score 47/100 (Watch) — see indicators →
https://arcusbio.com
Company Profile ↓
$18.54
+84.29% 1Y
Mkt Cap$2.36B
P/E-4.71
P/B6.91
52W High$31.57
52W Low$9.91
Book Value$3.65
EPS (TTM)$-3.94

Company Overview

Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's development product portfolio includes Casdatifan, a HIF-2a inhibitor for the treatment of kidney cancer; Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial for lung and gastrointestinal cancers; and Zimberelimab, an anti-PD-1 antibody. It also develops Quemliclustat, a small molecule inhibitor that targets the CD73 enzyme in the ATP-adenosine pathway, which is in phase 3 and phase 1/1b clinical trial for lung and pancreatic cancer. In addition, the company develops AB598, a CD39 antibody, which is in phase 1/1b clinical study for gastrointestinal cancer and AB801, an AXL inhibitor, which is in Phase 1b clinical trial for lung cancer. It has clinical collaboration with AstraZeneca for the Phase 3 PACIFIC-8 trial evaluating domvanalimab and durvalumab in Stage 3 NSCLC and for a Phase 1/1b study evaluating casdatifan and volrustomig in IO-naive patients with ccRCC; BVF Partners L.P. to support the discovery and development of compounds for the treatment of inflammatory diseases; and Bristol-Myers Squibb Company to develop a novel treatment regimen that delivers tumor control in kidney cancer. Arcus Biosciences, Inc. was incorporated in 2015 and is based in Hayward, California.

Why Investors Should Care

Steady Revenue Expansion

Revenue has grown at a 48.3% CAGR over the past five years.

Recent Developments

  • Dec 2025 Revenue of $33.00M (-35.3% YoY); net profit $-353.00M.
  • Trailing 12 Months Year-on-year growth — revenue -74.4%.
  • 5-Year Trend Long-term compounding — revenue CAGR 48.3%.

Growth & Price Performance

Compounded Sales Growth

5 Years:48.27%
1 Year:-74.40%

Stock Price Performance

1 Year:+84.29%
6 Months:-27.29%
3 Months:-33.41%
1 Month:-26.02%

Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.

Technical Snapshot Bearish
52-Week Range 40% of range
$9.91 $31.57
Trend Signals
  • Price vs 50-DMABelow
  • Price vs 200-DMABelow
  • RSI (14)27.51 · Oversold
Price Performance
1M-26.02%
3M-33.41%
6M-27.29%
1Y+84.29%

Auto-generated from price history and fundamentals; not investment advice.

⚙Ad space

Price Chart

Robinhood TradingView

Fundamental Growth Charts

Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.

PROS

  • Compounding revenue at 48.3% over 5 years.
  • In a confirmed uptrend (50-DMA above 200-DMA).

CONS

  • Trading 41.3% below its 52-week high.

* The pros and cons are auto-generated from financial metrics.

⚙Ad space

Valuation

Stock P/E
-4.71
Industry PE
25.45
Forward P/E
-5.48
PEG Ratio
-
Book Value
$3.65
Price to Book
6.91
P/S
27.47
EV/EBITDA
-5.78
Dividend Yield
0.00%

Growth (CAGR)

Revenue 5Y
48.27%
Profit 5Y
-
Revenue (YoY)
-74.40%
Earnings (YoY)
-

Profitability & Returns

ROCE
-42.51%
ROE
-90.82%
ROA
-30.39%
Profit Margin
0.00%
Op Margin
-
Gross Margin
0.00%
EPS (Latest Qtr)
$-0.72
EPS (TTM)
$-3.94

Balance Sheet & Liquidity

Debt/Equity
0.51
Quick Ratio
3.75
Current Ratio
3.82
Debt
$238.00M
Total Assets
$924.00M
Current Assets
$844.00M
Working Capital
$635.00M

Ownership

Promoter Holding
28.80%
Chg in Prom Hold
-0.36%
FII / Inst Holding
74.92%
Chg in FII Hold
0.14%

Financial Snapshot

Enterprise Value
$2.36B
Total Revenue (TTM)
$117.00M
EBITDA
$-476.00M
Free Cash Flow
$-270.62M
Operating Cash Flow
$-474.00M
Shares Outstanding
127.33M
Gross Margin
0.00%
Payout Ratio
0.00%

Peer comparison

Peer companies in the same sector (Healthcare).

#NameCMP $P/E Mkt CapDiv Yld % ROCE %ROE % Rev CAGR 5Y %Profit CAGR 5Y %
1 RCUS Arcus Biosciences, Inc. R2KR3KPHARMA 18.54 -4.71 $2.36B 0.00% -42.51% -90.82% 48.27% -
2 LLY Eli Lilly and Company SPXR3KPHARMA 1,273.46 42.83 $1.14T 0.60% - 102.29% 7.20% 11.41%
3 JNJ Johnson & Johnson SPXR3KPHARMA 263.81 30.60 $635.76B 1.98% 14.88% 25.74% 2.43% 4.76%
4 ABBV AbbVie Inc. SPXR3KPHARMA 285.64 80.69 $504.76B 2.54% 10.47% -129.24% 1.75% -29.06%
5 UNH UnitedHealth Group Incorporated SPXR3KPHARMA 418.09 26.85 $375.28B 2.47% 9.74% 14.15% 10.40% 5.43%
6 MRK Merck & Co., Inc. SPXR3KPHARMA 145.27 116.22 $358.41B 2.31% - 6.96% 5.64% 10.01%
7 NVS Novartis AG PHARMA 151.12 22.83 $287.24B 3.36% 21.09% 30.35% 9.25% 26.22%
8 AZN AstraZeneca PLC NDXPHARMA 171.49 25.63 $265.96B 2.00% 15.97% 21.96% 9.82% 45.96%
9 TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA 673.82 36.30 $249.14B 0.29% 8.14% 13.51% 8.81% 12.95%
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios

Quarterly Results

Figures in USD.

Metric Mar 2017Jun 2017Sep 2017Dec 2017Mar 2018Jun 2018Sep 2018Dec 2018Mar 2019Jun 2019Sep 2019Dec 2019Mar 2020Jun 2020Sep 2020Dec 2020Mar 2021Jun 2021Sep 2021Mar 2022Jun 2022Sep 2022Mar 2023Jun 2023Sep 2023Mar 2024Jun 2024Sep 2024Mar 2025Jun 2025Sep 2025Mar 2026Jun 2026
Revenue --------1.75M1.75M1.75M-1.75M1.75M64.53M-9.46M9.46M9.46M18.00M27.00M33.00M25.00M29.00M32.00M10.00M11.00M7.00M8.00M8.00M6.00M7.00M33.00M
Operating Income -7.30M-9.66M-23.13M--13.33M-15.90M-12.14M--18.77M-29.16M-23.25M--28.40M-45.38M1.55M--72.75M-76.14M-78.14M-67.00M-69.00M-70.00M-86.00M-83.00M-80.00M-16.00M-106.00M-105.00M-122.00M-8.00M-142.00M-134.00M-96.00M
Net Income -7.20M-9.55M-23.12M-13.21M-12.95M-13.53M-10.81M-12.29M-17.67M-28.09M-22.35M-16.60M-27.75M-45.07M1.82M-51.85M-72.59M-75.97M-77.97M-68.00M-67.00M-65.00M-80.00M-75.00M-71.00M-4.00M-93.00M-92.00M-112.00M0-135.00M-128.00M-91.00M
Diluted EPS -----------0.51---0.03----1.11---0.90-1.09-1.04-0.94-0.05-1.02-1.00-1.140.00-1.27-1.02-0.72
R&D Expense 5.80M7.83M21.43M-11.65M13.70M12.86M-15.55M25.00M17.24M-23.14M35.69M51.80M-66.39M68.77M71.25M61.00M70.00M77.00M81.00M84.00M82.00M109.00M115.00M123.00M122.00M139.00M141.00M122.00M113.00M

Profit & Loss (Annual)

Figures in USD.

Metric Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Revenue -1.41M8.35M15.00M78.00M383.00M38.00M37.00M51.00M33.00M
Operating Income -18.18M-53.44M-54.86M-88.71M-124.00M54.00M-280.00M-340.00M-330.00M-386.00M
Net Income -17.97M-53.08M-49.59M-84.71M-123.00M53.00M-267.00M-307.00M-283.00M-353.00M
Diluted EPS ----1.93-2.240.71-3.71-4.15-3.14-3.29
R&D Expense 14.25M47.22M49.65M78.48M159.00M257.00M288.00M340.00M448.00M523.00M

Balance Sheet (Annual)

Figures in USD.

Metric Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Total Assets --190.49M274.93M203.11M772.29M1.59B1.34B1.09B1.15B1.14B
Total Equity -2.17M-19.99M-72.33M234.94M164.00M502.00M842.00M657.00M462.00M485.00M631.00M
Cash & Equivalents 46.87M65.16M98.43M71.06M57.94M173.41M148.00M206.00M127.00M150.00M222.00M
Long Term Debt --------048.00M99.00M
Total Liabilities --36.62M39.98M39.27M269.99M750.45M----
Current Liabilities --12.73M16.93M22.71M121.67M166.00M193.00M184.00M226.00M231.00M

Cash Flows (Annual)

Figures in USD.

Metric Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Operating Cash Flow -12.94M-25.06M-43.00M-73.46M111.00M-438.00M-306.00M-170.00M-482.00M
Investing Cash Flow -38.86M-49.07M-113.44M59.21M-434.00M--413.00M194.00M-84.00M66.00M
Financing Cash Flow 70.10M107.40M129.07M1.12M439.00M-33.00M33.00M277.00M488.00M
Capital Expenditure -4.10M-5.51M-3.74M-1.93M-3.00M--6.00M-24.00M-6.00M-2.00M
Free Cash Flow -17.04M-30.57M-46.74M-75.39M108.00M-432.00M-330.00M-176.00M-484.00M
Net Change in Cash ------58.00M-79.00M23.00M72.00M
Share Buybacks --094.00K------

Ratios (Annual)

Figures in %.

Metric Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Gross Margin % ----------
Operating Margin % --3,782.1%-656.8%-591.4%-159.0%14.1%-736.8%-918.9%-647.1%-1,169.7%
Net Margin % --3,756.7%-593.7%-564.7%-157.7%13.8%-702.6%-829.7%-554.9%-1,069.7%
ROE % 89.9%73.4%-21.1%-51.7%-24.5%6.3%-40.6%-66.5%-58.4%-55.9%
ROCE % --30.1%-21.3%-49.2%-19.1%3.8%-24.3%-37.3%-35.7%-42.5%

Shareholding Pattern

Insiders
28.80%
Institutions
74.92%
Public Float
105.21%

Top Institutional Holders

#Holder% HeldSharesValue
1 Gilead Sciences Inc 24.68% 31.42M $767.08M
2 Blackrock Inc. 12.89% 16.42M $400.72M
3 State Street Corporation 4.74% 6.03M $147.18M
4 Wellington Management Group, LLP 4.63% 5.90M $143.91M
5 Montanova Capital LLC 3.75% 4.78M $116.59M
6 Vanguard Portfolio Management LLC 3.51% 4.48M $109.25M
7 FMR, LLC 3.18% 4.05M $98.85M
8 Vanguard Capital Management LLC 3.05% 3.89M $94.91M
9 Citadel Advisors Llc 2.46% 3.14M $76.53M
10 Woodline Partners LP 2.36% 3.01M $73.42M

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for RCUS

Google News Wed, 21 Oct 2026

Arcus Biosciences, Inc. (RCUS) Stock Forecasts - Yahoo Finance

<a href="https://news.google.com/rss/articles/CBMijwFBVV95cUxPcnR4M1BtTndILXRldjMwSGpveld0bzlQaERsdVd5T1hLTFd5b3pRNnVfLXZ1UnIzcDVtcHNvY1F4T3k0YzUzRkJQS0NMUmNENVJTMDVEb01iVUE0NWxtYmRBNS1fZEQtM25HMV9WUGJSOVhBenlOa3VTanpCN0NYWEN2MWxUcjEyTVh3RE…

Google News Wed, 21 Oct 2026

Arcus Biosciences (RCUS) Shares Plunge Nearly 20% Amid Clinical Data Release and Stock Offering - GuruFocus

<a href="https://news.google.com/rss/articles/CBMiywFBVV95cUxQaGh2c3AwbkR1QjAxZjBfNFpEYTZRWUVyUmZRRnpBNThNUGdyUHhTSnJOQThlUFJ4b2NITGQ2Ymt1ZUF6UUlVYzc3T2plQmF4TEdyUENNTWpSLW5RQlVPOU05dG1sdHBjMDZMWVltb19mRVRsQ2YwS2JXMVdCM3pkNEZPWVF4eGJaQjFCbn…

Google News Wed, 21 Oct 2026

Arcus Biosciences slides 20% on stock offering, kidney-cancer data (RCUS:NYSE) - Seeking Alpha

<a href="https://news.google.com/rss/articles/CBMipAFBVV95cUxOc1A4LWI0WUtvWWJyUTNZRG5vTTYtNzQyNkZBb2ZfT2pSdndldXlqMDFBRFZjdTVuUjFURUg1NDRmLVFOTnZBSXBacGRxUXFtVUZTN1B2dG0xZW04WkRFdk52STUxZHFEalpGaDNJdWVVYml3S0FkVWZOZDY3ekFXMEQtQTVIem1nOU90RF…

Google News Wed, 21 Oct 2026

Arcus Biosciences stock falls on public offering announcement - Investing.com

<a href="https://news.google.com/rss/articles/CBMiugFBVV95cUxQanVRYi1zcG1vSHJjanBMZ1doZHVOYlh3U0JwdG1JbjZOSzJBenptUlRBeFNrNTBacEJFbjZQYTh0QkRjYUlDUFJJTzhNOUVLQlNUQ0FtRkdqRExDUWhBNDMzTmk3VWxWZ0FsamUta1BTTUpBN09McHQxOGY0b0dmNnozaHV3amVTRXhsZn…

Google News Wed, 21 Oct 2026

A public stock offering has begun at Arcus Biosciences, but its size and completion remain uncertain. - Stock Titan

<a href="https://news.google.com/rss/articles/CBMiuAFBVV95cUxNcVhVTlJzenU4SXhJWW92UGRZSXR0alFXMU1tM09UcUxNeUtENmJack5zMmVkVlFDWlhnWm9uMEt2OW5KSy1lTDZsRGZ3RFdSTkpRM1pBdHpDaXI3eVJweEllNjQzV2tZbEJZNEJ3b2pTQkY3bk5QbWF0WGlfZ1MxaFBDdVBTSnlRQ0lWZ3…

Google News Fri, 23 Oct 2026

Is Arcus Biosciences (RCUS) Too Expensive After New Trial Data? - Simply Wall Street

<a href="https://news.google.com/rss/articles/CBMi4wFBVV95cUxNa2JGZUd0MmoyNTRTVk5HcDJrUE5NVUVlSGZZTWF1VTMwMjhiVXNOYkcxXzByZWxPR0tlZW1oQ1lERktObnBtOVJMVmpUcFhBZkZrdUZOb1hGQTVGbWZPSC0tX3JfZUtWLTBjakNpS3B2alVlUmF4cFFKQkhtZEhyVTJ2R0tDYUg2dWdQNV…

RCUS — Frequently Asked Questions

What is the current share price of Arcus Biosciences, Inc. (RCUS)?

As of 2026-10-23 16:27 PDT, Arcus Biosciences, Inc. (RCUS) trades at $18.54 on NYSE. Its 52-week range is $9.91 to $31.57.

What is the market capitalisation of RCUS?

Arcus Biosciences, Inc. (RCUS) has a market capitalisation of $2.36B on NYSE.

What is the P/E ratio of RCUS?

RCUS trades at a trailing price-to-earnings (P/E) ratio of -4.71. The industry average P/E is 25.45. Its price-to-book (P/B) ratio is 6.91.

What is the return on equity (ROE) of RCUS?

RCUS has a return on equity (ROE) of -90.82%. Its return on capital employed (ROCE) is -42.51%.

Is RCUS a good stock to buy?

This page provides a data-driven analysis of Arcus Biosciences, Inc. (RCUS), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.

Explore More

📊 Healthcare Sector 🔍 All Stock Screens 📈 Technical Screens 💰 Fundamental Screens 🔄 Swing Trading Setups 📐 Chart Patterns 📅 Earnings Calendar 📋 All USA Stocks
⚙Ad space